Alvotech and DKSH extend biosimilar partnership in Asia
.jpg)
The companies will commercialize six new biosimilar candidates addressing multiple therapeutic areas.
Alvotech and DKSH, a healthcare provider across 36 emerging countries in South-East Asia, have agreed to expand their strategic partnership to commercialize six new biosimilar product candidates for the Asian markets.
The initial pipeline contains biosimilar candidates addressing multiple therapeutic areas.
In March 2020, the companies announced its exclusive partnership agreement for AVT02, a biosimilar monoclonal antibody to AbbVie’s HUMIRA, which is a leading drug indicated for the treatment of several autoimmune diseases, including rheumatoid arthritis, ankylosing spondylitis, plaque psoriasis, psoriatic arthritis, ulcerative colitis, and Crohn’s disease amongst other indications.
The collaboration includes the following markets: Taiwan, Korea, Hong Kong, Philippines, Vietnam, Thailand, Cambodia, Myanmar, Malaysia, Singapore, Indonesia, India, Bangladesh and Pakistan.
These biosimilar candidates’ brand values are estimated around US$1.5 billion in annual sales in the Asia Pacific region, according to IQVIA data.
In the last 12 months, Alvotech has made notable strategic partnership agreements with leading regional and global industry players including: Teva in the US, Stada in Europe, JAMP in Canada, Yas Holding in the Middle East and Fuji Pharma in Japan.
Related News
-
.png)
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
.png)
News The 2024 Pharma Outsourcing Forecast: strategic partnerships across global landscapes
For the pharmaceutical industry, outsourcing drug development, manufacturing, and research operations to contract organisations is not just a passing trend – increasingly, the partnership between drug sponsor and drug vendor is one of vital impor... -
.png)
News Gerresheimer predicts weight-loss drug deals to account for 4% of yearly growth
Dietmar Siemssen, CEO of German primary packaging manufacturer Gerresheimer, states that approximately 4% of the company’s revenue growth each year to come from deals with drugmakers of weight loss and diabetes products, particularly GLP-1 class ... -
.png)
News Novel approach to creating sustainable packaging from rice husks
Researchers have created a new approach to the designing of eco-friendly nanofibres extracted from rice husks, addressing the critical need for sustainable packaging materials in food and biopharmaceutical products. -
.png)
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
.png)
News Coronary drug-coated medical device receives US FDA approval
Boston Scientific announced the FDA approval of their medical device AGENT Drug-Coated Balloon (DCB) for the indication of coronary in-stent restenosis in coronary artery disease patients. -
.png)
News CPHI Online Webinar Series – Innovative Strategies for B2B Pharma Marketeers
On February 20, 2024, CPHI Online hosted a webinar on Innovative Strategies for B2B Pharma Marketeers. Featuring expert speakers from across the pharmaceutical value chain, this webinar delves into how B2B pharma marketeers can create better content to... -
.png)
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance